NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has agreed to acquire CynoGen, a molecular diagnostics laboratory doing business as PersonalizeDx, for $2 million in cash plus stock.

Through the deal, Rosetta will pick up PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab in Lake Forest, Calif.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.